Ishikawa Tetsuya, Hagiwara Keitaro, Ochiya Takahiro
Core Facilities for Research and Innovative Medicine, National cancer Center Research Institute, Tokyo, Japan.
Methods Mol Biol. 2012;826:103-14. doi: 10.1007/978-1-61779-468-1_9.
A method for the generation of human induced pluripotent stem (iPS) cells was established. This method employs adenovirus carrying the ecotropic retrovirus receptor mCAT1 and Moloney murine leukemia virus (MMLV)-based retroviral vectors carrying the four transcription factors POU5F1 (OCT3/4), KLF4, SOX2, and MYC (c-Myc) (Masaki H & Ishikawa T Stem Cell Res 1:105-15, 2007). The differentiation of human iPS cells into hepatic cells was performed by a stepwise protocol (Song Z et al. Cell Res 19:1233-42, 2009). These cells have potential as patient-specific in vitro models for studying disease etiology and could be used in drug discovery programs tailored to deal with genetic variations in drug efficacy and toxicity.
建立了一种生成人类诱导多能干细胞（iPS细胞）的方法。该方法采用携带嗜亲性逆转录病毒受体mCAT1的腺病毒以及携带四种转录因子POU5F1（OCT3/4）、KLF4、SOX2和MYC（c-Myc）的基于莫洛尼鼠白血病病毒（MMLV）的逆转录病毒载体（正木H和石川T，《干细胞研究》1:105 - 15，2007年）。人类iPS细胞向肝细胞的分化通过逐步方案进行（宋Z等人，《细胞研究》19:1233 - 42，2009年）。这些细胞有潜力作为研究疾病病因的患者特异性体外模型，并可用于针对药物疗效和毒性方面的基因变异量身定制的药物研发项目。
